Molecular Cancer Research

雜志介紹

Molecular Cancer Research雜志介紹

《Molecular Cancer Research》是一本以English為主的未開放獲取國際優秀期刊，中文名稱分子癌癥研究，本刊主要出版、報道醫學-腫瘤學領域的研究動態以及在該領域取得的各方面的經驗和科研成果，介紹該領域有關本專業的最新進展，探討行業發展的思路和方法，以促進學術信息交流，提高行業發展。該刊已被國際權威數據庫SCI、SCIE收錄，為該領域相關學科的發展起到了良好的推動作用，也得到了本專業人員的廣泛認可。該刊最新影響因子為5.8，最新CiteScore 指數為9.6。

本刊近期中國學者發表的論文主要有：

• Synergistic DBNDD1-GDF15 Signaling Activates the NF-κB Pathway to Promote Colorectal Cancer Progressio

  Author: Qi, Xiaomin; Bai, Caijuan; Dong, Li; Wang, Anqi; Wei, Chaojun; Li, Yonghong; Zhao, Mengyuan; You, Chongge

• Targeting LAMP2A Enhances SELENBP1 Expression and Suppresses Malignant Behaviors in HNSC

  Author: Cao, Hongwei; Xing, Dongsheng; Yu, Hanbing; Jiang, Feifei; Qi, Li; Wang, Kunrong; Wang, Yan; Yan, Aihui

• SOX4-Mediated Post-transcriptional Suppression of PTEN via miR-106b～25 Cluster Contributes to Prostate Cancer Aggressivenes

  Author: Sun, Feifei; Gao, Lin; Wang, Meng; Liu, Ping; Wang, Baozhen; Hu, Jing; Wang, Weiqing; Liu, Hui; Han, Bo

• ACYP2 Induces Temozolomide Resistance in Glioblastoma by Promoting PARP1-Mediated DNA Damage Repai

  Author: Sui, Mengjun; Cai, Qing; Sun, Zhiwei; Li, Jinjin; Zhang, Yiyang; Li, Mengdan; Dai, Penggao; Li, Gang

英文介紹

Molecular Cancer Research雜志英文介紹

Molecular Cancer Research publishes articles describing novel basic cancer research discoveries of broad interest to the field. Studies must be of demonstrated significance, and the journal prioritizes analyses performed at the molecular and cellular level that reveal novel mechanistic insight into pathways and processes linked to cancer risk, development, and/or progression. Areas of emphasis include all cancer-associated pathways (including cell-cycle regulation; cell death; chromatin regulation; DNA damage and repair; gene and RNA regulation; genomics; oncogenes and tumor suppressors; signal transduction; and tumor microenvironment), in addition to studies describing new molecular mechanisms and interactions that support cancer phenotypes. For full consideration, primary research submissions must provide significant novel insight into existing pathway functions or address new hypotheses associated with cancer-relevant biologic questions.